1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Sato, A. Kawaguchi, K. Kimura, K. Tanimura, R. Sone, S. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking To be Published 0353 A peptide mimetic of IFN, the first proof of a small peptidic agonist for heterodimeric cytokine receptor 10.2210/pdb1id6/pdb pdb_00001id6 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 1 SINGLE WAVELENGTH M 1 1.0 1784.942 SYR6 1 syn polymer no no SVQARWEAAFDLDLY SVQARWEAAFDLDLY A polypeptide(L) n n n n n n n n n n n n n n n database_2 pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Database references Derived calculations 1 0 2002-04-10 1 1 2008-04-27 1 2 2011-07-13 1 3 2022-02-23 _database_2.pdbx_DOI _database_2.pdbx_database_accession RCSB Y PDBJ 2001-04-04 REL REL chemically synthesized sample These structures were determined using standard 2D homonuclear techniques. structures with the least restraint violations 750 11 DQF-COSY TOCSY 2D NOESY ambient 293 K The structures are based on 66 NOE-derived distance constraints. 4D simulated annealing 3 fewest violations 2.0mM SYR6; deuterated dimethyl sulfoxide 100% deuterated dimethyl sulfoxide 100% Morikawa, S. et. al. structure solution EMMBOSS 5.0 Morikawa, S. et. al. refinement EMMBOSS 5.0 600 Varian INOVA SER 1 n 1 SER 1 A VAL 2 n 2 VAL 2 A GLN 3 n 3 GLN 3 A ALA 4 n 4 ALA 4 A ARG 5 n 5 ARG 5 A TRP 6 n 6 TRP 6 A GLU 7 n 7 GLU 7 A ALA 8 n 8 ALA 8 A ALA 9 n 9 ALA 9 A PHE 10 n 10 PHE 10 A ASP 11 n 11 ASP 11 A LEU 12 n 12 LEU 12 A ASP 13 n 13 ASP 13 A LEU 14 n 14 LEU 14 A TYR 15 n 15 TYR 15 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A VAL 2 -13.10 1 A ARG 5 11.53 1 A TRP 6 13.07 1 A ASP 11 -13.46 1 A LEU 12 -13.89 2 A GLN 3 -12.85 2 A ALA 4 -12.58 3 A GLN 3 -12.38 3 A ARG 5 10.09 4 A ALA 4 -17.91 4 A TRP 6 11.19 4 A GLU 7 -10.27 4 A ALA 8 -12.26 4 A PHE 10 14.26 4 A LEU 12 -14.08 5 A ALA 4 -10.62 5 A ARG 5 11.44 6 A ARG 5 12.50 6 A TRP 6 10.79 6 A ALA 8 -10.98 7 A GLN 3 -12.61 7 A ARG 5 10.29 7 A ALA 8 -11.11 7 A LEU 12 -10.86 8 A VAL 2 -11.06 8 A GLN 3 -12.45 8 A ALA 4 12.96 8 A ARG 5 14.16 8 A PHE 10 11.38 9 A VAL 2 -10.67 9 A GLN 3 -11.39 9 A ARG 5 11.35 9 A ALA 8 -11.94 10 A VAL 2 -10.81 11 A SER 1 -11.27 11 A VAL 2 -11.35 11 A ARG 5 12.74 1 A VAL 2 63.55 -103.42 1 A GLN 3 -164.17 -36.26 1 A ALA 4 53.14 -176.35 1 A ARG 5 48.16 27.17 1 A TRP 6 -162.29 -154.32 1 A GLU 7 -32.51 96.01 1 A ALA 8 57.81 -92.95 1 A ALA 9 170.39 127.10 1 A ASP 11 175.90 -30.49 1 A LEU 14 59.80 78.82 2 A VAL 2 39.32 -107.22 2 A GLN 3 -159.23 -33.57 2 A ALA 4 60.83 -179.95 2 A ARG 5 34.77 43.47 2 A TRP 6 -154.09 -151.59 2 A GLU 7 -38.30 -81.18 2 A ALA 9 -41.02 156.13 2 A PHE 10 -142.41 -87.88 2 A LEU 12 -142.97 -48.57 2 A ASP 13 39.57 51.67 2 A LEU 14 78.68 111.30 3 A VAL 2 -73.84 -98.18 3 A GLN 3 -133.52 -39.87 3 A ALA 4 51.36 -175.11 3 A ARG 5 37.15 42.23 3 A TRP 6 -156.45 -149.06 3 A GLU 7 -50.81 -96.37 3 A PHE 10 -119.32 -86.20 3 A ASP 13 37.68 29.67 4 A VAL 2 -93.22 -79.43 4 A GLN 3 -145.59 -35.51 4 A ALA 4 65.09 179.35 4 A ARG 5 31.72 40.13 4 A TRP 6 -142.68 -153.30 4 A GLU 7 -33.99 -31.30 4 A ALA 8 -168.00 -76.38 4 A ALA 9 159.94 142.74 4 A PHE 10 -126.54 -95.84 4 A LEU 12 -130.01 -62.52 4 A ASP 13 39.55 56.52 4 A LEU 14 -97.20 41.96 5 A VAL 2 -83.86 -92.94 5 A GLN 3 -146.22 -45.10 5 A ALA 4 55.15 -171.24 5 A ARG 5 34.69 35.66 5 A TRP 6 -147.82 -148.34 5 A GLU 7 -36.61 -29.96 5 A ALA 8 -169.44 -68.61 5 A ALA 9 159.61 120.17 5 A PHE 10 -131.44 -71.78 5 A LEU 12 -172.51 -43.98 6 A VAL 2 37.91 -100.41 6 A GLN 3 -157.30 -61.34 6 A ALA 4 76.99 -15.38 6 A ARG 5 -98.94 40.07 6 A TRP 6 -141.85 -145.25 6 A GLU 7 -35.72 -31.22 6 A ALA 8 -163.63 -75.86 6 A ALA 9 175.63 133.77 6 A PHE 10 -112.53 -92.67 6 A LEU 12 -104.68 -75.10 6 A LEU 14 -93.84 45.56 7 A VAL 2 38.63 -110.13 7 A GLN 3 -166.83 -31.41 7 A ALA 4 47.95 174.43 7 A TRP 6 -162.16 -148.46 7 A GLU 7 -36.69 -75.45 7 A ALA 8 -105.57 -93.67 7 A ALA 9 164.97 160.99 7 A PHE 10 -130.40 -84.69 7 A LEU 12 -160.42 30.98 7 A LEU 14 -151.86 -69.62 8 A VAL 2 -69.04 -99.22 8 A GLN 3 -170.74 -36.21 8 A ALA 4 81.10 -62.88 8 A TRP 6 -164.87 -148.51 8 A GLU 7 -44.33 -96.80 8 A ALA 9 -36.90 148.23 8 A PHE 10 -129.03 -83.92 8 A LEU 14 168.66 49.05 9 A VAL 2 -68.60 -100.17 9 A GLN 3 -159.55 -35.66 9 A ALA 4 47.29 173.56 9 A TRP 6 -165.83 -148.71 9 A GLU 7 -35.67 -71.07 9 A ALA 8 -111.05 -93.26 9 A ALA 9 163.97 151.57 9 A PHE 10 -109.56 -60.27 9 A ASP 11 -164.59 -40.96 9 A LEU 14 -176.18 39.37 10 A VAL 2 -129.82 -77.96 10 A GLN 3 -151.86 -50.64 10 A ALA 4 70.90 -179.86 10 A ARG 5 48.83 28.93 10 A TRP 6 -155.43 -149.84 10 A GLU 7 -38.59 96.30 10 A ALA 8 43.87 -97.80 10 A ALA 9 -177.05 140.46 10 A PHE 10 -104.35 -91.83 10 A ASP 13 50.33 19.51 10 A LEU 14 38.83 32.13 11 A VAL 2 31.86 -101.77 11 A GLN 3 -160.43 -41.08 11 A ALA 4 49.51 171.24 11 A TRP 6 -174.03 -151.76 11 A GLU 7 -41.47 97.02 11 A ALA 8 51.42 -94.25 11 A ALA 9 174.19 134.58 11 A PHE 10 -83.56 -75.65 11 A ASP 11 -141.83 -77.71 11 A ASP 13 33.84 57.24 11 A LEU 14 -171.19 31.20 SOLUTION STRUCTURES OF SYR6 1 N N ANTIVIRAL PROTEIN SYR6, ANTIVIRAL PROTEIN BAB62415 GB 1 15076606 1 15 1ID6 1 15 15076606 A 1 1 15